Information Provided By:
Fly News Breaks for December 12, 2016
XLRN
Dec 12, 2016 | 16:16 EDT
Oppenheimer analyst Leah Cann initiated Acceleron with an Outperform and a $44 price target saying the successful launch of two experimental products, Luspatercept and Dalantercept, could result in Acceleron having revenues grow to $367.3 million in 2021 from $18.1 million in 2015.
News For XLRN From the Last 2 Days
There are no results for your query XLRN